NASDAQ:GHDX - Genomic Health Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$67.55 +0.17 (+0.25 %)
(As of 09/19/2018 11:07 AM ET)
Previous Close$67.80
Today's Range$67.48 - $67.80
52-Week Range$26.54 - $67.74
Volume1,653 shs
Average Volume254,480 shs
Market Capitalization$2.33 billion
P/E Ratio6,762.00
Dividend YieldN/A
Beta0.44
Genomic Health logoGenomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; the Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading; and Oncotype DX AR-V7 Nucleus Detect test for men with metastatic castration-resistant prostate cancer. The company offers its products through a network of distributors. Genomic Health, Inc. has collaboration agreement with Epic Sciences, Inc.; license and development agreement with Biocartis N.V.; license agreement with Cleveland Diagnostics, Inc.; and a research collaboration agreement with Janssen Pharmaceuticals. The company was founded in 2000 and is based in Redwood City, California.

Receive GHDX News and Ratings via Email

Sign-up to receive the latest news and ratings for GHDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Medical laboratories
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:GHDX
CUSIP37244C10
Phone650-556-9300

Debt

Debt-to-Equity RatioN/A
Current Ratio5.39
Quick Ratio5.39

Price-To-Earnings

Trailing P/E Ratio6,762.00
Forward P/E Ratio125.09
P/E GrowthN/A

Sales & Book Value

Annual Sales$340.75 million
Price / Sales7.11
Cash Flow$0.3622 per share
Price / Cash186.48
Book Value$5.41 per share
Price / Book12.49

Profitability

EPS (Most Recent Fiscal Year)$0.01
Net Income$-3,850,000.00
Net Margins1.18%
Return on Equity9.09%
Return on Assets7.41%

Miscellaneous

Employees863
Outstanding Shares35,850,000
Market Cap$2.33 billion

Genomic Health (NASDAQ:GHDX) Frequently Asked Questions

What is Genomic Health's stock symbol?

Genomic Health trades on the NASDAQ under the ticker symbol "GHDX."

How were Genomic Health's earnings last quarter?

Genomic Health, Inc. (NASDAQ:GHDX) issued its quarterly earnings results on Thursday, August, 2nd. The medical research company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.19. The medical research company had revenue of $95.60 million for the quarter, compared to analyst estimates of $92.23 million. Genomic Health had a net margin of 1.18% and a return on equity of 9.09%. The company's revenue was up 14.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.08) EPS. View Genomic Health's Earnings History.

When is Genomic Health's next earnings date?

Genomic Health is scheduled to release their next quarterly earnings announcement on Wednesday, November, 14th 2018. View Earnings Estimates for Genomic Health.

What guidance has Genomic Health issued on next quarter's earnings?

Genomic Health updated its FY18 earnings guidance on Thursday, August, 2nd. The company provided earnings per share (EPS) guidance of $0.39-0.56 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.45. The company issued revenue guidance of $366-382 million, compared to the consensus revenue estimate of $377.43 million.

What price target have analysts set for GHDX?

9 brokerages have issued 1 year price objectives for Genomic Health's stock. Their predictions range from $25.00 to $62.00. On average, they expect Genomic Health's stock price to reach $42.75 in the next twelve months. This suggests that the stock has a possible downside of 37.0%. View Analyst Price Targets for Genomic Health.

What is the consensus analysts' recommendation for Genomic Health?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genomic Health in the last year. There are currently 2 sell ratings, 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Genomic Health.

Who are some of Genomic Health's key competitors?

Who are Genomic Health's key executives?

Genomic Health's management team includes the folowing people:
  • Ms. Kimberly J. Popovits, Chairman, CEO & Pres (Age 59)
  • Dr. Steven Shak, Co-Founder, Chief Scientific Officer & Chief Medical Officer (Age 67)
  • Mr. G. Bradley Cole, Chief Financial Officer (Age 62)
  • Dr. Frederic G. Pla, Chief Operating Officer (Age 59)
  • Mr. James J. Vaughn, Chief U.S. Commercial Officer (Age 55)

Has Genomic Health been receiving favorable news coverage?

News headlines about GHDX stock have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Genomic Health earned a media and rumor sentiment score of 0.18 on Accern's scale. They also gave media headlines about the medical research company an impact score of 46.57 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. View Recent Headlines for Genomic Health.

Who are Genomic Health's major shareholders?

Genomic Health's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.66%), Millennium Management LLC (4.03%), Renaissance Technologies LLC (3.92%), Schwab Charles Investment Management Inc. (0.94%), Northern Trust Corp (0.79%) and Eagle Asset Management Inc. (0.73%). Company insiders that own Genomic Health stock include Fred E Cohen, Frederic Pla, G Bradley Cole, James J Vaughn, Kimberly J Popovits, Laura Leber, Phillip G Febbo and Steven Shak. View Institutional Ownership Trends for Genomic Health.

Which major investors are selling Genomic Health stock?

GHDX stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., Schwab Charles Investment Management Inc., Bank of America Corp DE, Eagle Asset Management Inc., First Trust Advisors LP, BlueMountain Capital Management LLC, Alambic Investment Management L.P. and California Public Employees Retirement System. Company insiders that have sold Genomic Health company stock in the last year include Fred E Cohen, Frederic Pla, G Bradley Cole, James J Vaughn, Kimberly J Popovits, Laura Leber, Phillip G Febbo and Steven Shak. View Insider Buying and Selling for Genomic Health.

Which major investors are buying Genomic Health stock?

GHDX stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, Acadian Asset Management LLC, Castleark Management LLC, EAM Investors LLC, BlackRock Inc., GSA Capital Partners LLP and Capital Impact Advisors LLC. View Insider Buying and Selling for Genomic Health.

How do I buy shares of Genomic Health?

Shares of GHDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Genomic Health's stock price today?

One share of GHDX stock can currently be purchased for approximately $67.8047.

How big of a company is Genomic Health?

Genomic Health has a market capitalization of $2.33 billion and generates $340.75 million in revenue each year. The medical research company earns $-3,850,000.00 in net income (profit) each year or $0.01 on an earnings per share basis. Genomic Health employs 863 workers across the globe.

How can I contact Genomic Health?

Genomic Health's mailing address is 301 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The medical research company can be reached via phone at 650-556-9300 or via email at [email protected]


MarketBeat Community Rating for Genomic Health (NASDAQ GHDX)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  245 (Vote Outperform)
Underperform Votes:  312 (Vote Underperform)
Total Votes:  557
MarketBeat's community ratings are surveys of what our community members think about Genomic Health and other stocks. Vote "Outperform" if you believe GHDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GHDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel